Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism
نویسندگان
چکیده
منابع مشابه
Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism.
Kenkre and colleagues report the absence of correlation between FcγRIIIa-V158F polymorphism and rituximab response in follicular lymphoma patients, a result which is in contrast with prior studies. This discrepancy recalls that many other factors (from the host and from the tumor) may influence the efficacy of rituximab in vivo.
متن کاملSignificance of FcγRIIIa-V158F Polymorphism-Letter.
Cartron and colleagues in their commentary (CCR Translations) present an informative discussion of several putative host and tumor factors that may explain the conflicting reports of correlation between FcgRIIIa-V158F polymorphism and response to rituximab and other mAbs (1). To their list of possible variables influencing the outcome of mAb therapy, I would like to add the extensive genetic po...
متن کاملAre Clinically Insignificant Prostate Cancers Really Insignificant among Korean Men?
PURPOSE We aimed to determine whether 12 core-extended biopsies of the prostate could predict insignificant prostate cancer (IPCa) in Koreans reliably enough to recommend active surveillance. MATERIALS AND METHODS Two hundred and ninety-seven patients who underwent radical prostatectomy after 12 core-extended prostate biopsies were retrospectively reviewed. 38 cases (12.8%) were shown to be I...
متن کاملManagement of Clinically Insignificant Residual Fragments following Shock Wave Lithotripsy
Clinically insignificant residual fragments (CIRFs) are small fragments (less than 5 mm) that are present in upper urinary tract at the time of regular post-SWL followup. The term is controversial because they may remain silent and asymptomatic or become a risk factor for stone growth and recurrence, leading to symptomatic events, and need further urologic treatment. Although a stone-free state...
متن کاملOverdiagnosis of breast cancer at screening is clinically insignificant.
Long-term follow-up of randomized trials provide the most accurate estimates of overdiagnosis. Estimates from follow-up of service screening studies are almost as accurate if there is sufficient adjustment for lead time and risk status. When properly analyzed data from both of these types of trials indicate that the rate of overdiagnosis at screening mammography is clinically negligible: 0-5%. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2015
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-15-2777